LXD1 Stock Overview
Supplies medical technology for critical care, operating theatre, and home healthcare applications worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Inspiration Healthcare Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.18 |
| 52 Week High | UK£0.64 |
| 52 Week Low | UK£0.18 |
| Beta | 0.062 |
| 11 Month Change | -21.98% |
| 3 Month Change | -44.82% |
| 1 Year Change | -71.50% |
| 33 Year Change | -88.40% |
| 5 Year Change | n/a |
| Change since IPO | -86.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| LXD1 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -29.3% | -0.2% | -0.5% |
| 1Y | -71.5% | -0.1% | 1.6% |
Return vs Industry: LXD1 underperformed the German Medical Equipment industry which returned 0.9% over the past year.
Return vs Market: LXD1 underperformed the German Market which returned 2.4% over the past year.
Price Volatility
| LXD1 volatility | |
|---|---|
| LXD1 Average Weekly Movement | 19.8% |
| Medical Equipment Industry Average Movement | 4.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: LXD1's share price has been volatile over the past 3 months.
Volatility Over Time: LXD1's weekly volatility has increased from 11% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 210 | Gordon Davis | www.inspiration-healthcare.com |
Inspiration Healthcare Group plc, together with its subsidiaries, supplies medical technology for critical care, operating theatre, and home healthcare applications worldwide. The company provides SLE6000, a technology for little lungs; LifeStart, a bedside resuscitation unit; First Breath, a neonatal non-invasive support; Inspire rPAP, a 2-piece non-invasive system for the resuscitation of infants; Genedrive MT-RNR1 system, a care genetic test used to detect mitochondrial gene MT-RNR1 in human buccal cells; Unique+ cerebral function monitoring (CFM) used to help in the diagnosis of brain injury; and push-to-set intermittent, paediatric intermittent, neonatal intermittent, and 2-Mode Continuous regulators, as well as Ohio medical MRI compatible vacuum regulators. It offers inspire nCPAP used for treating infants; anatomical face masks; mini stat CO2, stat CO2, and neostat CO2; ALGOPEDOL; and heel warmers products.
Inspiration Healthcare Group plc Fundamentals Summary
| LXD1 fundamental statistics | |
|---|---|
| Market cap | €14.09m |
| Earnings (TTM) | -€7.46m |
| Revenue (TTM) | €44.41m |
0.3x
P/S Ratio-1.9x
P/E RatioIs LXD1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LXD1 income statement (TTM) | |
|---|---|
| Revenue | UK£37.63m |
| Cost of Revenue | UK£19.74m |
| Gross Profit | UK£17.89m |
| Other Expenses | UK£24.21m |
| Earnings | -UK£6.32m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.093 |
| Gross Margin | 47.53% |
| Net Profit Margin | -16.80% |
| Debt/Equity Ratio | 23.0% |
How did LXD1 perform over the long term?
See historical performance and comparison